Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Cyclacel Pharmaceuticals Stock Down 5.4%

CYCC stock opened at $7.52 on Friday. Cyclacel Pharmaceuticals has a 12-month low of $3.08 and a 12-month high of $597.60. The company has a market cap of $11.88 million, a price-to-earnings ratio of -0.01 and a beta of 0.08. The company has a 50 day moving average of $7.59 and a two-hundred day moving average of $41.46.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Wednesday, August 13th. The biotechnology company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($72.00) by $71.02.

Insider Activity at Cyclacel Pharmaceuticals

In other news, major shareholder David E. Lazar sold 6,750 shares of the stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.36, for a total transaction of $83,430.00. Following the transaction, the insider owned 155,838 shares in the company, valued at $1,926,157.68. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 51.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC lifted its holdings in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 118.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,269,485 shares of the biotechnology company’s stock after purchasing an additional 689,024 shares during the quarter. Armistice Capital LLC owned approximately 0.61% of Cyclacel Pharmaceuticals worth $354,000 as of its most recent SEC filing. Institutional investors own 23.58% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.